List of Arazlo drug patents

Arazlo is owned by Bausch.

Arazlo contains Tazarotene.

Arazlo has a total of 1 drug patent out of which 0 drug patents have expired.

Arazlo was authorised for market use on 18 December, 2019.

Arazlo is available in lotion;topical dosage forms.

Arazlo can be used as topical treatment of acne vulgaris in patients 9 years of age and older.

The generics of Arazlo are possible to be released after 11 May, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311482 BAUSCH Topical compositions and methods for treating skin diseases
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

How can I launch a generic of ARAZLO before it's patent expiration?
More Information on Dosage

ARAZLO family patents

13

United States

2

Canada

2

Japan

2

Brazil

2

European Union

1

Portugal

1

Hungary

1

Korea, Republic of

1

Slovenia

1

Croatia

1

Poland

1

Australia

1

RS

1

Denmark

1

Mexico

1

Lithuania

1

Spain

1

China

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic